Skip to content
Home
About
About the conference
AMR Conference 2021 – Summer Edition
Speakers
AMR Conference 2020
AMR Stakeholder Guide
COVID-19 Survey
Digital Poster Gallery
Participants 2020
Programme 2020
Recordings 2020
AMR Conference 2019
AMR Conference 2022
Impressions 2022
Partnering
Programme
Start-up Pitch
Academic Poster Presentation
Sponsors
AMR 2022 Stakeholder Guide
News
Keep me informed
Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals
Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals
Moderator:
John Rex, Chief Medical Officer, F2G Ltd.
Speakers:
Sumathi Nambiar – Director Division of Anti-Infective Products, Office of Infectious Diseases, FDA
Marco Cavalieri – Head of Antiinfectives and Vaccines, Safety&Efficacy Sector, EMA
Play Video
This might also be of interest for you:
Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea
, public workshop by FDA, NIAID and CDC
COVID-19: EMA sets up infrastructure for real-world monitoring of treatments and vaccines
Launch of public consultation on joint network strategy to 2025
, 6 July
×